Literature DB >> 24183455

Results of adjunctive spinal drainage and/or left subclavian artery bypass in thoracic endovascular aortic repair.

Dean J Arnaoutakis1, George J Arnaoutakis1, Robert J Beaulieu1, Christopher J Abularrage1, Ying Wei Lum1, James H Black2.   

Abstract

BACKGROUND: The adjunctive use of a preoperative cerebrospinal fluid (CSF) drain and/or left subclavian artery (LSA) bypass for thoracic endovascular aortic repair (TEVAR) to minimize neurologic complications remains controversial.
METHODS: A retrospective review was conducted of a prospective database of patients undergoing TEVAR from April 2005 through August 2012. CSF drainage was performed under local anesthesia in a staged fashion prior to TEVAR. When possible, LSA bypass was also performed prior to TEVAR. Adjunctive procedures were not performed for patients in emergent operations. Preoperative characteristics, operative variables, outcomes, neurologic complications, and survival status were recorded.
RESULTS: Ninety patients underwent TEVAR at our institution during the study period with a mean follow-up of 23 months (IQR 7-50). Mean age was 67.3 years (SD 13.8) and 48 (53%) were male. One (1%) patient had a connective tissue disorder. Sixty-six (73%) patients presented with degenerative aneurysm, 13 (14%) with chronic type B dissection, 6 (7%) with pseudoaneurysm, and 5 (6%) with traumatic aortic pathology. Fourteen (16%) had acute ruptures. Sixty-seven (74%) patients underwent adjunctive procedures for TEVAR including a CSF drain (n = 48, 53%), LSA bypass (n = 7, 8%), or both (n = 12, 13%). CSF drain placement was uncomplicated in all instances. Cerebral ischemia was seen in 2 (2%), which recovered with further surgical therapy. Embolic stroke was appreciated in 1 (1%). Delayed spinal cord ischemia (SCI) occurred in 3 (3%) patients and was reversed with hypertensive therapy in 2 to ambulatory status at discharge. The 30-day permanent SCI and mortality were 0.9% and 3%, respectively. CSF drain placement was associated with improved 1-year survival (P = 0.03).
CONCLUSIONS: Our use of adjunctive procedures for TEVAR demonstrated better SCI results compared with those of prior reports of selective CSF drainage when SCI arises. Our approach was associated with improved 1-year survival. Preoperative CSF drain placement allows for rapid, intensive therapy for SCI and should be considered when clinically feasible.
Copyright © 2014 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2013        PMID: 24183455     DOI: 10.1016/j.avsg.2013.06.011

Source DB:  PubMed          Journal:  Ann Vasc Surg        ISSN: 0890-5096            Impact factor:   1.466


  5 in total

1.  Effects of preemptive cerebrospinal fluid drainage on spinal cord protection during thoracic endovascular aortic repair.

Authors:  Seungjun Song; Suk-Won Song; Tae Hoon Kim; Kwang-Hun Lee; Kyung-Jong Yoo
Journal:  J Thorac Dis       Date:  2017-08       Impact factor: 2.895

2.  Periaortic air in native and post-operative aorta on computed tomography.

Authors:  Mansi Verma; Amit Ajit Deshpande; Niraj Nirmal Pandey; Sanjeev Kumar
Journal:  Br J Radiol       Date:  2021-09-30       Impact factor: 3.039

3.  Association between aortic coverage and spinal cord ischemia after endovascular repair of type B aortic dissection.

Authors:  Mansi Verma; Vineeta Ojha; Amit Ajit Deshpande; Surya Pratap Singh; Pradeep Ramakrishnan; Sanjeev Kumar
Journal:  Indian J Thorac Cardiovasc Surg       Date:  2022-05-11

4.  Cohort comparison of thoracic endovascular aortic repair with open thoracic aortic repair using modern end-organ preservation strategies.

Authors:  Dean J Arnaoutakis; George J Arnaoutakis; Christopher J Abularrage; Robert J Beaulieu; Ashish S Shah; Duke E Cameron; James H Black
Journal:  Ann Vasc Surg       Date:  2015-03-07       Impact factor: 1.466

Review 5.  Spinal cord injury after thoracic endovascular aortic aneurysm repair.

Authors:  Hamdy Awad; Mohamed Ehab Ramadan; Hosam F El Sayed; Daniel A Tolpin; Esmerina Tili; Charles D Collard
Journal:  Can J Anaesth       Date:  2017-10-10       Impact factor: 5.063

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.